{
  "source": "PA-Notification-Reyvow.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1325-6\nProgram Prior Authorization-Notification\nMedication Reyvow® (lasmiditan)\nP&T Approval Date 8/2020, 7/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nReyvow (lasmiditan) is a serotonin 5-HT receptor agonist indicated for the acute treatment of\n1F\nmigraine with or without aura in adults.\nThe American Headache Society recommends use of NSAIDs (including aspirin), non-opioid\nanalgesics, acetaminophen, or caffeinated analgesic combinations (e.g.,\naspirin/acetaminophen/caffeine) for mild‐to‐moderate attacks and migraine‐specific agents\n(i.e.,triptans, dihydroergotamine [DHE]) for moderate or severe attacks and mild‐to‐moderate\nattacks that respond poorly to NSAIDs or caffeinated combinations.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Reyvow will be approved based on all of the following criteria:\na. Diagnosis of migraine headaches with or without aura.\n-AND-\nb. Used for acute treatment of migraine\n-AND-\nc. Patient is 18 years of age or older\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Reyvow will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Supply limits may apply.\n• Prior Authorization-Medical Necessity may apply\n• Step Therapy may apply\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Reyvow [package i",
    "aim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Reyvow [package insert]. Indianapolis, IN: Lilly USA, LLC; September 2022.\n2. The American Headache Society Position Statement on Integrating New Migraine Treatments Into\nClinical Practice. AHS Consensus Statement. Headache. 2021; 61:1021-39.\nProgram Prior Authorization-Notification – Reyvow\nChange Control\nDate Change\n8/2020 New program.\n7/2021 Annual review. Updated references. Added state mandate language.\n3/2022 Updated references.\n3/2023 Annual review. Updated references.\n3/2024 Annual review. No changes.\n3/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}